Anderson Raymond sold $351K of MNPR
Anderson Raymond sold 3,142 shares of Monopar Therapeutics (MNPR) at an average of $111.77 ($110.04–$113.05, $0.35M total) across 3 trades on 2026-08-25 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale is modest and unlikely to affect MNPR's valuation significantly.
Market read
Provides a fresh, primary‑source insider transaction for MNPR; useful for short‑term monitoring.
What to watch
Director retains a sizable position (23,751 shares) and the sale was executed under a 10b5‑1 plan.
Background
Form 4 filings disclose insider transactions; directors often use 10b5‑1 plans for scheduled sales.
Ticker impact
Director Anderson Raymond sold 3,142 shares for $351,189 via a 10b5‑1 plan on 2026‑08‑25.
Minor downward pressure; unlikely to move price materially.
The sale represents ~13% of the director's remaining stake and is disclosed under a pre‑arranged plan, limiting interpretive weight.
Market effects
Biotech sector may see slight scrutiny of insider activity but no broader impact.
US market only; no regional ripple effect.
Limited to investors tracking MNPR.
Counterpoint
The sale could be routine liquidity management rather than a negative signal.
Key entities
- CompanyMonopar Therapeutics
Biotech firm developing therapies for rare diseases.
- IndividualAnderson Raymond
Director of Monopar Therapeutics.
